About Mannin Research
Mannin Research is a company based in Toronto (Canada) founded in 2012 was acquired by QBioMed in October 2015.. Mannin Research offers products and services including Glaucoma Eye Drop, Tie2 Activator, and Proprietary Research Platform. Mannin Research operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Calliditas Therapeutics, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mannin Research Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$7.5 M (USD), Grant
Nov 05, 2019
-
Investors
National Research Council Canada
& 1 more
-
Employee Count
Employee Count
-
Acquired by
QBioMed
(Oct 30, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mannin Research
Mannin Research offers a comprehensive portfolio of products and services, including Glaucoma Eye Drop, Tie2 Activator, and Proprietary Research Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Eye drop designed to reduce intra-ocular pressure for glaucoma treatment
Compound for protecting kidney in acute kidney injury cases
Platform for developing new vascular disease therapeutics
Funding Insights of Mannin Research
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $7.5M
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2019 | Amount | Grant - Mannin Research | Valuation |
investors |
|
| Nov, 2017 | Amount | Grant - Mannin Research | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mannin Research
Mannin Research has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include National Research Council Canada and QBioMed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Scientific and technological research is conducted for Canada's benefit.
|
Founded Year | Domain | Location | |
|
Chemotherapeutic agents for hepatocellular carcinoma are developed using uttroside B.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mannin Research
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mannin Research
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mannin Research Comparisons
Competitors of Mannin Research
Mannin Research operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Calliditas Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mannin Research
Frequently Asked Questions about Mannin Research
When was Mannin Research founded?
Mannin Research was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Where is Mannin Research located?
Mannin Research is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
What does Mannin Research do?
Mannin Research was founded in 2012 and is based in Toronto, Canada. Focus is placed on the biotechnology sector, where therapeutics for vascular diseases are developed. The lead candidate, MAN-01, is a small-molecule eye drop in pre-clinical stages for Primary Open Angle Glaucoma, targeting reduction of intraocular pressure. A second candidate for cystic kidney disease remains in the discovery stage. Operations center on advancing these programs toward clinical applications.
Who are the top competitors of Mannin Research?
Mannin Research's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
What products or services does Mannin Research offer?
Mannin Research offers Glaucoma Eye Drop, Tie2 Activator, and Proprietary Research Platform.
Who are Mannin Research's investors?
Mannin Research has 2 investors. Key investors include National Research Council Canada, and QBioMed.